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FRI0048 THE ANTI-CD20 ANTIBODY RITUXIMAB REDUCES THE INFLAMMATORY AND PROTHROMBOTIC PROFILE OF LEUKOCYTES FROM RHEUMATOID ARTHRITIS PATIENTS AND MODULATES THE ACTIVITY OF ENDOTHELIAL CELLS
Background: Rituximab (RTX) has been shown to be successful in the treatment of rheumatoid arthritis (RA), indicating that B cells have an important role in this disease. Objectives: The present study was undertaken to investigate the mechanisms of action of RTX on the immune and endothelial cells (EC) of the vascular system in the setting of RA. Methods: Purified lymphocytes from five RA patients with high disease activity were treated with RTX (1ug/mL) for 24 hours. Then, the depletion of B cells was assessed by flow cytometry, and the changes occurred in the inflammatory profile of T-lymphocytes was analysed by RT-PCR. In a second set of experiments, to evaluate the influence of B-cell depletion on the inflammatory/prothrombotic profile of cells belonging to the vascular system, supernatants from cultured lymphocytes of RA patients in the presence or in the absence of RTX were added to isolated monocytes from AR patients and to cultured endothelial cells. The response to RTX was then examined. Results: As expected, RTX promoted a significant depletion of B-cells. In parallel, the inflammatory profile of T lymphocytes from RA patients was downregulated, as shown by a significant drop of IL-1, IL-6, IL-17, IFN and TNF expression levels, thus suggesting that the anti-inflammatory effects of RTX might be related to B cell depletion. Supernatants from RTX-treated lymphocytes further abridged the prothrombotic profile of RA-monocytes, promoting a significant inhibition of TF, MCP-1, IL-8, IL-1 and VEGF-A gene expression. Moreover, endothelial cells, activated after treatment with supernatants from cultured RA-lymphocytes, showed reduced expression of cell-adhesion molecules (i.e. V-CAM, I-CAM, E-Selectin) and pro-thrombotic factors (i.e. TF, VEGF, IL-8) after treatment with supernatants from cultured RA-lymphocytes in the presence of RTX. Methods: AIA was induced by injection of mBSA into knee joints of mice previously immunized with mBSA/CFA. Joint inflammation, bone destruction, number of TRAP + osteoclasts and S100A8/A9 positive cells was determined using histology and immunohistochemistry. In vitro osteoclastogenesis was assessed using TRAP staining. Results: Seven days after induction of AIA, we observed decreased inflammation and bone erosion in the knee joints of FcγRI,II,III,IV -/-mice compared to WT. The ability of bone marrow cells of FcγRI,II,III,IV -/-mice to differentiate into osteoclasts in vitro was comparable to the one of WT controls. Moreover, we observed comparable numbers of TRAP + osteoclasts on the bone surface of FcγRI/II/III/IV -/-and WT arthritic mice, suggesting that the observed decrease in bone erosion is mainly caused by a reduced osteoclast activity, rather than decreased osteoclast number. However, in contrast to FcγRI/II/III/IV -/-, AIA induction in knee joints of FcγRI/II/III -/-resulted in increased bone erosion and inflammation compared to WT, highlighting the possible crucial role of FcγRIV in the pathology. Interestingly, the number of PMNs infiltrated in the knee joint of FcγRI/II/III -/-resulted increased, whereas it was decreased in the knee joints of FcγRI/II/III/IV -/-compared to their WT controls. This observation suggests that particularly FcγRIV is involved in regulating influx of PMNs. PMNs are potent producers of alarmins S100A8/A9 which are described to promote osteoclast activity. In line the number of S100A8/A9 positive cells in synovium was increased in FcγRI/II/III -/-while decreased in FcγRI/II/III/IV -/-, compared to their WT control. Conclusions: FcγRIV promotes bone erosion in AIA by enhancing influx of PMNs within the synovium. PMNs are potent producers of S100A8/A9 which has been described to induce osteoclast activity. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.5386
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